 | Up a level |
Merten, Hannes; Brandl, Fabian; Zimmermann, Martina; Schaefer, Jonas V; Irpinio, Linda; Sand, Kine M K; Nilsen, Jeannette; Andersen, Jan Terje; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2021). Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling. European journal of pharmaceutics and biopharmaceutics, 167, pp. 104-113. Elsevier 10.1016/j.ejpb.2021.07.011
Brandl, Fabian; Busslinger, Sarah; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2020). Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life. Journal of controlled release, 327, pp. 186-197. Elsevier 10.1016/j.jconrel.2020.08.004
Schwalm, Stephanie; Erhardt, Martin; Römer, Isolde; Pfeilschifter, Josef; Zangemeister-Wittke, Uwe; Huwiler, Andrea (2020). Ceramide Kinase Is Upregulated in Metastatic Breast Cancer Cells and Contributes to Migration and Invasion by Activation of PI 3-Kinase and Akt. International journal of molecular sciences, 21(4) MDPI 10.3390/ijms21041396
Brandl, Fabian; Merten, Hannes; Zimmermann, Martina; Béhé, Martin; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2019). Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins. Journal of controlled release, 307, pp. 379-392. Elsevier 10.1016/j.jconrel.2019.06.030
Lorenzer, Cornelia; Streußnig, Sonja; Tot, Emilia; Winkler, Anna-Maria; Merten, Hannes; Brandl, Fabian; Sayers, Edward J; Watson, Peter; Jones, Arwyn T; Zangemeister-Wittke, Uwe; Plückthun, Andreas; Winkler, Johannes (2019). Targeted delivery and endosomal cellular uptake of DARPin-siRNA bioconjugates: Influence of linker stability on gene silencing. European journal of pharmaceutics and biopharmaceutics, 141, pp. 37-50. Elsevier 10.1016/j.ejpb.2019.05.015
Merten, Hannes; Schaefer, Jonas V; Brandl, Fabian; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2019). Facile Site-Specific Multiconjugation Strategies in Recombinant Proteins Produced in Bacteria. Methods in molecular biology, 2033, pp. 253-273. Springer 10.1007/978-1-4939-9654-4_17
Blanchard, Olivier; Stepanovska, Bisera; Starck, Manuel Thierry; Erhardt, Martin; Römer, Isolde; Meyer Zu Heringdorf, Dagmar; Pfeilschifter, Josef; Zangemeister-Wittke, Uwe; Huwiler, Andrea (2018). Downregulation of the S1P Transporter Spinster Homology Protein 2 (Spns2) Exerts an Anti-Fibrotic and Anti-Inflammatory Effect in Human Renal Proximal Tubular Epithelial Cells. International journal of molecular sciences, 19(5) MDPI 10.3390/ijms19051498
Huwiler, Andrea; Zangemeister-Wittke, Uwe (2018). The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives. Pharmacology & therapeutics, 185, pp. 34-49. Elsevier 10.1016/j.pharmthera.2017.11.001
Graumann, Rebecca; Di Capua, Gabriella A; Oyarzún, Juan E; Vásquez, Marcos A; Liao, Christine; Brañes, Jorge A; Roa, Iván; Casanello, Paola; Corvalán, Alejandro H; Owen, Gareth I; Delgado, Iris; Zangemeister-Wittke, Uwe; Ziegler, Annemarie (2017). Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer. PLoS ONE, 12(5), e0177244. Public Library of Science 10.1371/journal.pone.0177244
Filipenko, Iuliia; Schwalm, Stephanie; Reali, Luca; Pfeilschifter, Josef; Fabbro, Doriano; Huwiler, Andrea; Zangemeister-Wittke, Uwe (2016). Upregulation of the S1P3 receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE2 and EP2/EP4 activation. Biochimica et biophysica acta (BBA) - molecular and cell biology of lipids, 1861(11), pp. 1840-1851. Elsevier 10.1016/j.bbalip.2016.09.005
Simon, Hans-Uwe; Zangemeister-Wittke, Uwe (2016). Myelosuppression. In: Schwab, Manfred (ed.) Encyclopedia of Cancer. Heidelberg: Springer
Filipenko, Iuliia; Huwiler, Andrea (2016). The role of the S1P3 receptor in inflammation-associated proliferative disorders (Submitted). (Dissertation, Graduate School for Cellular and Biomedical Sciences, University of Bern, Faculty of Medicine)
Merten, Hannes; Brandl, Fabian; Plückthun, Andreas; Zangemeister-Wittke, Uwe (2015). Antibody-Drug Conjugates for Tumor Targeting-Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins. Bioconjugate chemistry, 26(11), pp. 2176-2185. American Chemical Society 10.1021/acs.bioconjchem.5b00260
Schwalm, Stephanie; Maneva Timcheva, Tankica; Filipenko, Iuliia; Ebadi, Mahsa; Hofmann, Lotte P; Zangemeister-Wittke, Uwe; Pfeilschifter, Josef; Huwiler, Andrea (2015). Sphingosine kinase 2 deficiency increases proliferation and migration of renal mouse mesangial cells and fibroblasts. Biological chemistry, 396(6-7), pp. 813-825. De Gruyter 10.1515/hsz-2014-0289
Pastukhov, Oleksandr; Schalm, Stephanie; Zangemeister-Wittke, Uwe; Fabbro, Doriano; Bornancin, Frederic; Japtok, Lukasz; Kleuser, Burkhrad; Pfeilschifter, Josef; Huwiler, Andrea (2014). The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death. British journal of pharmacology, 171(24), pp. 5829-5844. Wiley-Blackwell 10.1111/bph.12886
Stefan, Nikolas; Zimmermann, Martina; Simon, Manuel; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2014). Novel Prodrug-Like Fusion Toxin with Protease-Sensitive Bioorthogonal PEGylation for Tumor Targeting. Bioconjugate chemistry, 25(12), pp. 2144-2156. American Chemical Society 10.1021/bc500468s
Thangaiyan, Rabi; Huwiler, Andrea; Zangemeister-Wittke, Uwe (2014). AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells. Molecular carcinogenesis, 53(7), pp. 578-588. Wiley 10.1002/mc.22012
Simon, Manuel; Stefan, Nikolas; Borsig, Lubor; Plückthun, Andreas; Zangemeister-Wittke, Uwe (2014). Increasing the Antitumor Effect of an EpCAM-Targeting Fusion Toxin by Facile Click PEGylation. Molecular cancer therapeutics, 2(13), pp. 375-385. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-13-0523
Pastukhov, Oleksandr; Schalm, Stephanie; Römer, Isolde; Pfeilschifter, Josef; Huwiler, Andrea; Zangemeister-Wittke, Uwe (2014). Ceramide kinase contributes to proliferation but not to prostaglandin E2 formation in renal mesangial cells and fibroblasts. Cellular physiology and biochemistry, 34(1), pp. 119-133. Karger 10.1159/000362989
Wojtalla, Anna; Fischer, Barbara; Kotelevets, Nataliya; Mauri, Francesco A; Sobek, Jens; Rehrauer, Hubert; Wotzkow, Carlos; Tschan, Mario P; Seckl, Michael J; Zangemeister-Wittke, Uwe; Arcaro, Alexandre (2013). Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer. Clinical cancer research, 19(1), pp. 96-105. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-12-1138
Simon, Manuel; Frey, Raphael; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2013). Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension. Bioconjugate chemistry, 24(11), pp. 1955-1986. American Chemical Society 10.1021/bc4004102
Simon, Manuel; Stefan, Nikolas; Plückthun, Andreas; Zangemeister-Wittke, Uwe (2013). Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert opinion on drug delivery, 10(4), pp. 451-468. Taylor & Francis 10.1517/17425247.2013.759938
Kotelevets, Nataliya; Fabbro, Doriano; Huwiler, Andrea; Zangemeister-Wittke, Uwe (2012). Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis. PLoS ONE, 7(6), e39209. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0039209
Heine, Markus; Freund, Barbara; Nielsen, Peter; Jung, Caroline; Reimer, Rudolph; Hohenberg, Heinrich; Zangemeister-Wittke, Uwe; Wester, Hans-Juergen; Lüers, Georg H; Schumacher, Udo (2012). High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS ONE, 7(5), e36258. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0036258
Simon, Manuel; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2012). Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries. Bioconjugate chemistry, 23(2), pp. 279-86. Washington, D.C.: American Chemical Society 10.1021/bc200591x
Zangemeister-Wittke, Uwe; Simon, Hans-Uwe (2012). Myelosuppression. In: Schwab, Manfred (ed.) Encyclopedia of Cancer (pp. 2437-2440). Heidelberg: Springer-Verlage 10.1007/978-3-642-16483-5
Patricia, Martin-Killias; Stefan, Nikolas; Rothschild, Sacha; Plückthun, Andreas; Zangemeister-Wittke, Uwe (2011). A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clinical cancer research, 17(1), pp. 100-10. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-10-1303
Huwiler, Andrea; Bourquin, Florence; Kotelevets, Nataliya; Pastukhov, Oleksandr; Capitani, Guido; Grütter, Markus G; Zangemeister-Wittke, Uwe (2011). A prokaryotic S1P lyase degrades extracellular S1P in vitro and in vivo: implication for treating hyperproliferative disorders. PLoS ONE, 6(8), e22436. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0022436
Huwiler, Andrea; Kotelevets, Nataliya; Xin, Cuiyan; Pastukhov, Oleksandr; Pfeilschifter, Josef; Zangemeister-Wittke, Uwe (2011). Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage. British journal of pharmacology, 162(2), pp. 532-43. Oxford: Wiley-Blackwell 10.1111/j.1476-5381.2010.01053.x
Stefan, Nikolas; Martin-Killias, Patricia; Wyss-Stoeckle, Sascha; Honegger, Annemarie; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2011). DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. Journal of molecular biology, 413(4), pp. 826-43. Amsterdam: Elsevier 10.1016/j.jmb.2011.09.016
Lange, Annika; Gustke, Heike; Glassmeier, Günter; Heine, Markus; Zangemeister-Wittke, Uwe; Schwarz, Jürgen R; Schumacher, Udo; Lange, Tobias (2011). Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro. Lung cancer, 74(2), pp. 178-87. Amsterdam: Elsevier 10.1016/j.lungcan.2011.03.017
Zangemeister-Wittke, Uwe; Simon, Hans-Uwe (2009). Myelosuppression. In: Schwab, Manfred (ed.) Encyclopedia of Cancer, 2nd Edition (pp. 2008-2010). Heidelberg: Springer Verlag 10.1007/978-3-540-47648-1_3940
Winkler, Johannes; Martin-Killias, Patricia; Plückthun, Andreas; Zangemeister-Wittke, Uwe (2009). EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Molecular cancer therapeutics, 8(9), pp. 2674-83. Philadelphia, Pa.: American Association for Cancer Research AACR 10.1158/1535-7163.MCT-09-0402
Sodeur, Stephan; Ullrich, Sebastian; Gustke, Heike; Zangemeister-Wittke, Uwe; Schumacher, Udo (2009). Increased numbers of spontaneous SCLC metastasis in absence of NK cells after subcutaneous inoculation of different SCLC cell lines into pfp/rag2 double knock out mice. Cancer letters, 282(2), pp. 146-51. Amsterdam: Elsevier 10.1016/j.canlet.2009.03.005
Mousavi-Shafaei, Parisa; Ziaee, Abed-Ali; Zangemeister-Wittke, Uwe (2009). Increased cytotoxicity of cisplatin in SK-MEL 28 melanoma cells upon down-regulation of melanoma inhibitor of apoptosis protein Iran Biomed J
Marinov, Marin; Ziogas, Algirdas; Pardo, Olivier E; Tan, Liwen Terence; Dhillon, Tony; Mauri, Francesco A; Lane, Heidi A; Lemoine, Nicholas R; Zangemeister-Wittke, Uwe; Seckl, Michael J; Arcaro, Alexandre (2009). AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clinical cancer research, 15(4), pp. 1277-87. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-08-2166
Belyanskaya, Larisa L; Ziogas, Algirdas; Hopkins-Donaldson, Sally; Kurtz, Stefanie; Simon, Hans-Uwe; Stahel, Rolf; Zangemeister-Wittke, Uwe (2008). TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung cancer, 60(3), pp. 355-65. Amsterdam: Elsevier 10.1016/j.lungcan.2007.11.005
Hussain, Sajid; Plückthun, Andreas; Allen, Theresa M; Zangemeister-Wittke, Uwe (2007). Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Molecular cancer therapeutics, 6(11), pp. 3019-27. Philadelphia, Pa.: American Association for Cancer Research AACR 10.1158/1535-7163.MCT-07-0615
Giorgini, Simona; Trisciuoglio, Daniela; Gabellini, Chiara; Desideri, Marianna; Castellini, Laura; Colarossi, Cristina; Zangemeister-Wittke, Uwe; Zupi, Gabriella; Del Bufalo, Donatella (2007). Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Molecular cancer research, 5(8), pp. 761-71. Philadelphia, Pa.: American Association for Cancer Research AACR 10.1158/1541-7786.MCR-07-0088
Huwiler, Andrea; Zangemeister-Wittke, Uwe (2007). Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Critical reviews in oncology, hematology, 63(2), pp. 150-9. Boca Raton, Fla.: Elsevier 10.1016/j.critrevonc.2007.04.010
Zangemeister-Wittke, Uwe (2007). Krebsbehandlung mit Antisensemolekülen. Onkologe, 13(2007), pp. 256-262. Heidelberg: Springer-Medizin-Verlag
Zangemeister-Wittke, Uwe (2007). Antisense molecules for targeted cancer therapy. Onkologe, 13(3), pp. 256-262. Springer-Medizin-Verlag 10.1007/s00761-006-1170-z
Zangemeister-Wittke, Uwe; Huwiler, Andrea (2006). Antisense targeting of Mcl-1 has therapeutic potential in gastric cancer. Cancer biology & therapy, 5(10), pp. 1355-1356. Georgetown, Tex.: Landes Bioscience 10.4161/cbt.5.10.3488
Hussain, Sajid; Plückthun, Andreas; Allen, Theresa M; Zangemeister-Wittke, Uwe (2006). Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Molecular cancer therapeutics, 5(12), pp. 3170-80. Philadelphia, Pa.: American Association for Cancer Research AACR 10.1158/1535-7163.MCT-06-0412
Mousavi-Shafaei, Parisa; Ziaee, Abed-Ali; Azizi, Ebrahim; Zangemeister-Wittke, Uwe (2006). Antisense-mediated melanoma inhibitor of apoptosis protein downregulation sensitizes G361 melanoma cells to cisplatin. Anti-cancer drugs, 17(9), pp. 1031-9. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.cad.0000231474.77159.e3
Kubetzko, Susanne; Balic, Ela; Waibel, Robert; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2006). PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. Journal of biological chemistry, 281(46), pp. 35186-201. Bethesda, Md.: American Society for Biochemistry and Molecular Biology 10.1074/jbc.M604127200
Hopkins-Donaldson, Sally; Belyanskaya, Larisa L; Simões-Wüst, Ana Paula; Sigrist, Brigitte; Kurtz, Stefanie; Zangemeister-Wittke, Uwe; Stahel, Rolf (2006). p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia, 8(7), pp. 551-9. New York, N.Y.: Nature America 10.1593/neo.06148
Wacheck, V; Zangemeister-Wittke, Uwe (2006). Antisense molecules for targeted cancer therapy. Critical reviews in oncology, hematology, 59(1), pp. 65-73. Boca Raton, Fla.: Elsevier 10.1016/j.critrevonc.2005.10.004
Yamanaka, Kazuki; Rocchi, Palma; Miyake, Hideaki; Fazli, Ladan; So, Alan; Zangemeister-Wittke, Uwe; Gleave, Martin E (2006). Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU international, 97(6), pp. 1300-8. Oxford: Blackwell Science 10.1111/j.1464-410X.2006.06147.x
Altznauer, Frank; Martinelli, Sibylla; Yousefi, Shida; Thürig, Christine; Schmid, Inès; Conway, Edward M; Schöni, Martin H; Vogt, Peter; Mueller, Christoph; Fey, Martin F; Zangemeister-Wittke, Uwe; Simon, Hans-Uwe (2004). Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. The Journal of experimental medicine, 199(10), pp. 1343-1354. Rockefeller Univ. Press 10.1084/jem.20032033
